INKT

11.54

0.52% -0.06

Pre-mercato: 11.54

Mink Therapeutics Inc (INKT)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Precedente Chiudi:

$11.60

Aprire:

$11.88

Volume 24 ore:

15,603

Relative Volume:

0.05

Capitalizzazione di mercato:

$57.49M

Reddito:

Utile/perdita netta:

$-12.49M

Rapporto P/E:

-3.8923

EPS:

-2.9648

Flusso di cassa netto:

$-5.93M

1 W Prestazione:

+6.07%

1M Prestazione:

+7.95%

6M Prestazione:

-11.71%

1 anno Prestazione:

+52.05%

Intervallo 1D:

$11.31

$12.14

Intervallo di 1 settimana:

$10.71

$12.44

Portata 52W:

$6.34

$76.00

Mink Therapeutics Inc Stock (INKT) Company Profile

Nome

Mink Therapeutics Inc

Settore

Healthcare (1106)

Industria

Biotechnology (615)

Telefono

212-994-8250

Indirizzo

149 FIFTH AVENUE, NEW YORK

Dipendente

Cinguettio

Prossima data di guadagno

2026-05-21

Ultimi documenti SEC

INKT's Discussions on Twitter

Compare INKT vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
INKT Mink Therapeutics Inc	11.54	57.49M	0	-12.49M	-5.93M	-2.9648
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-08-15	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-07-14	Downgrade	William Blair	Outperform → Mkt Perform

Mink Therapeutics Inc Borsa (INKT) Ultime notizie

Apr 30, 2026

MiNK Therapeutics | DEF 14A: Definitive information statements - Moomoo

Apr 30, 2026

Board elections and auditor vote at MiNK Therapeutics (NASDAQ: INKT) - Stock Titan

Apr 30, 2026

Director Holcomb of MiNK Therapeutics (NASDAQ: INKT) receives 4,174 stock options grant - Stock Titan

Apr 30, 2026

MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Apr 30, 2026

Apr 28, 2026

Short Interest in MiNK Therapeutics, Inc. (NASDAQ:INKT) Drops By 30.6% - MarketBeat

Apr 28, 2026

Apr 27, 2026

Trading Systems Reacting to (INKT) Volatility - Stock Traders Daily

Apr 27, 2026

Apr 25, 2026

MiNK outlines initial ARDS phase II data in H2 2026 while extending runway through 2026 - MSN

Apr 25, 2026

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Apr 25, 2026

Apr 23, 2026

Buy Rating on MiNK Therapeutics Driven by Promising Phase 2 Survival Benefit and Immune Activation in PD-1–Refractory Gastric Cancer - TipRanks

Apr 23, 2026

INKT MiNK Therapeutics posts narrower Q4 2025 loss than expected, shares drop 9.78 percent on zero revenue. - Cổng thông tin điện tử Tỉnh Sơn La

Apr 23, 2026

Apr 22, 2026

MiNK Therapeutics (INKT) Stock Rights Issue (Weakens) 2026-04-22Professional Trade Ideas - UBND thành phố Hải Phòng

Apr 22, 2026

Apr 20, 2026

MiNK Therapeutics (INKT) Stock: Downside Risk (Crashes) 2026-04-20Real Time Stock Idea Network - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Agenus cancer cocktail records 0% response rate, missing midstage goal - BioSpace

Apr 20, 2026

Apr 18, 2026

MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer - Sahm

Apr 18, 2026

Melissa Orilall Net Worth (2026) - GuruFocus

Apr 18, 2026

Apr 17, 2026

In hard-to-treat gastroesophageal cancer, some patients lived 20+ months - Stock Titan

Apr 17, 2026

Apr 16, 2026

How Mink Therapeutics Inc. (INKT) Affects Rotational Strategy Timing - Stock Traders Daily

Apr 16, 2026

Apr 14, 2026

INKT SEC FilingsMink Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 14, 2026

The INKT Cell Story: Why Investors Need To Watch MiNK Therapeutics Closely - RTTNews

Apr 14, 2026

Apr 11, 2026

H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛

Apr 11, 2026

Apr 10, 2026

Retail Surge: What is MiNK Therapeutics Incs P E ratio telling us2026 Top Gainers & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Apr 10, 2026

Smart Money: Whats the fair value of MiNK Therapeutics Inc stockWeekly Stock Summary & AI Enhanced Trade Execution Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

MiNK Therapeutics (INKT) finance officer reports 222 indirect shares on Form 3 - Stock Titan

Apr 09, 2026

Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight - Dailyhunt

Apr 09, 2026

Fed Meeting: What is the target price for MiNK Therapeutics Inc stock2026 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn

Apr 09, 2026

Apr 08, 2026

MiNK Therapeutics – Three Weeks. Three Catalysts - Oncodaily

Apr 08, 2026

INKT PE Ratio & Valuation, Is INKT Overvalued - Intellectia AI

Apr 08, 2026

Could a short squeeze happen in MiNK Therapeutics (INKT) Stock | INKT Q4 Earnings: Beats Estimates by $0.28Rating Downgrade - Cổng thông tin điện tử Tỉnh Sơn La

Apr 08, 2026

Apr 07, 2026

MiNK Therapeutics clarifies status of potential combination trials and investments By Investing.com - Investing.com

Apr 07, 2026

Apr 06, 2026

Will MiNK Therapeutics (INKT) Stock Hit Record Highs | Price at $11.96, Up 11.93%Bearish Pattern - Xã Thanh Hà

Apr 06, 2026

Apr 05, 2026

New Phase II Data on BOT/BAL Combination in Gastroesophageal Cancer at AACR 2026Agenus - Oncodaily

Apr 05, 2026

(INKT) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 05, 2026

MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Recommendation of "Hold" by Brokerages - MarketBeat

Apr 05, 2026

Apr 04, 2026